Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis | Zendy

R P Moseley | Zendy; AG Davies | Zendy; RB Richardson | Zendy; Michael R. Zalutsky | Zendy; S Carrell | Zendy; John W. Fabre | Zendy; N.H. Slack | Zendy; J. Bullimore | Zendy; Barry Pizer | Zendy; Varnavas Papanastassiou | Zendy; JT Kemshead | Zendy; Hb Coakham | Zendy; LS Lashford | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis

Author(s) -

R P Moseley,

AG Davies,

RB Richardson,

Michael R. Zalutsky,

S Carrell,

John W. Fabre,

N.H. Slack,

J. Bullimore,

Barry Pizer,

Varnavas Papanastassiou,

JT Kemshead,

Hb Coakham,

LS Lashford

Publication year - 1990

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1990.345

Subject(s) - vomiting , medicine , nausea , intrathecal , meningitis , monoclonal antibody , toxicity , chemotherapy , meningeal carcinomatosis , central nervous system disease , monoclonal , cerebrospinal fluid , anesthesia , surgery , pathology , gastroenterology , antibody , immunology

Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research